4,587 Shares of Vertex Pharmaceuticals Incorporated $VRTX Bought by Factory Mutual Insurance Co.

Key Points

• Factory Mutual Insurance Co. opened a new Vertex Pharmaceuticals position, buying 4,587 shares worth approximately $2.4 million in the third quarter.
• Institutional investors and hedge funds hold 90.96% of Vertex’s shares; several major firms, including State Street and Wellington Management, increased their stakes.
• Vertex’s latest quarterly revenue rose 11.8% year over year to $3.44 billion, topping estimates, while EPS of $4.76 narrowly missed expectations. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $596.44.

Factory Mutual Insurance Co. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,587 shares of the pharmaceutical company's stock, valued at approximately $2,398,000.

Several other institutional investors have also recently added to or reduced their stakes in VRTX. BlackRock Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $11,975,849,000. State Street Corp grew its position in Vertex Pharmaceuticals by 1.2% in the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company's stock valued at $5,896,910,000 after buying an additional 141,320 shares during the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 1.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company's stock valued at $1,613,209,000 after buying an additional 35,069 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company's stock worth $1,533,248,000 after acquiring an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth $1,509,651,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
• Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
• Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
• Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an "overweight" rating in a report on Tuesday. Evercore raised their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an "outperform" rating in a research report on Wednesday, September 2nd. Morgan Stanley decreased their price target on Vertex Pharmaceuticals from $665.00 to $660.00 and set an "overweight" rating on the stock in a research note on Tuesday. Leerink Partners began coverage on shares of Vertex Pharmaceuticals in a research note on Monday, September 21st. They set an "outperform" rating and a $594.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the stock an "overweight" rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $596.44.

Vertex Pharmaceuticals Stock Up 3.4%

Shares of NASDAQ:VRTX opened at $549.04 on Thursday. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a 52-week low of $406.67 and a 52-week high of $568.67. The stock's fifty day simple moving average is $522.90 and its 200-day simple moving average is $480.92. The company has a market capitalization of $139.35 billion, a P/E ratio of 31.20, a P/E/G ratio of 2.56 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to analysts' expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.80 EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.64 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.